Furthermore, (Glu)E88, moves closer to site A. E88 together with D103 are thought to serve as ligands of the zinc(II) ion once it moves away from the two histidine ligands (H106 and H220) in site A. The two ZnT8 variants are targeted by different autoantibodies in type 1 diabetes, indicating that the mutation also affects epitope formation, although there is no apparent change in type 1 diabetes risk [27]. Here, SLC30A8 is linked to type 1 diabetes mellitus.